Mbx Biosciences, INC. (MBX) SEC Filings — 2025

Filings

• MBX Biosciences Boosts Cash by $173.8M, Losses Mount Amid R&D Push — 10-Q · Nov 6, 2025
• MBX Biosciences Enters Material Definitive Agreement — 8-K · Sep 26, 2025
• MBX Biosciences Files 8-K Report — 8-K · Sep 22, 2025
• MBX Biosciences Files 8-K — 8-K · Sep 4, 2025
• MBX Biosciences' Q2 Loss Widens Amid R&D Push — 10-Q · Aug 7, 2025
• MBX Biosciences Files 8-K — 8-K · Jun 16, 2025
• Mbx Biosciences, INC. 8-K Filing — 8-K · Jun 9, 2025
• MBX Biosciences: Director Departs, New Officers Elected — 8-K · Jun 6, 2025
• MBX Biosciences Files Q1 2025 10-Q — 10-Q · May 12, 2025
• MBX Biosciences Files 2024 Proxy Statement — DEF 14A · Apr 23, 2025
• MBX Biosciences Reports Director Departure, Officer Compensation — 8-K · Apr 7, 2025
• Mbx Biosciences, INC. 10-K Filing — 10-K · Mar 17, 2025
• MBX Biosciences Acquired by Aptalis Pharma for $100M — 8-K · Jan 7, 2025